Optical angiography1/31/2024 ![]() Intravascular imaging-guided PCI linked to key benefits The full analysis was published in The New England Journal of Medicine. ![]() “The results are also highly significant because only a single dose was needed, which could improve access to care and adherence to long-term drug regimens.” “Not only does the suppression of angiotensinogen hold promise for more effectively reducing hypertension for extended periods of time after injection, there is growing excitement over the possibility it also might be therapeutic for kidney and heart disease,” AHA’s editors wrote. Early data suggests taking zilebesiran for eight weeks is associated with reductions in key blood pressure measurements compared to a placebo higher doses are linked to higher reductions. Zilebesiran shows potential for preventing hypertensionĪ new investigational drug, zilebesiran, can decrease the production of angiotensinogen, a protein believed to contribute to a patient's risk of high blood pressure. “Particularly noteworthy were advances in technology to restore blood flow to blocked and narrowed arteries, potentially preventing death and disability for a wide range of patients, including those with severe illness.” “In 2023, investigators made important strides toward improving and extending the lives of people affected by these conditions, along with potentially lowering the burden of disease with therapies and strategies that hold promise for prevention,” the AHA editors wrote. With the end of the year rapidly approaching, the American Heart Association (AHA) editorial staff has published a list of some of 2023’s biggest breakthroughs in cardiovascular disease (CVD) research. ![]()
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |